245 related articles for article (PubMed ID: 20473136)
1. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers.
Serrano-Pozo A; Vega GL; Lütjohann D; Locascio JJ; Tennis MK; Deng A; Atri A; Hyman BT; Irizarry MC; Growdon JH
Alzheimer Dis Assoc Disord; 2010; 24(3):220-6. PubMed ID: 20473136
[TBL] [Abstract][Full Text] [Related]
2. 24S-hydroxycholesterol: a marker of brain cholesterol metabolism.
Lütjohann D; von Bergmann K
Pharmacopsychiatry; 2003 Sep; 36 Suppl 2():S102-6. PubMed ID: 14574622
[TBL] [Abstract][Full Text] [Related]
3. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain.
Locatelli S; Lütjohann D; Schmidt HH; Otto C; Beisiegel U; von Bergmann K
Arch Neurol; 2002 Feb; 59(2):213-6. PubMed ID: 11843691
[TBL] [Abstract][Full Text] [Related]
4. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease.
Hoglund K; Thelen KM; Syversen S; Sjogren M; von Bergmann K; Wallin A; Vanmechelen E; Vanderstichele H; Lutjohann D; Blennow K
Dement Geriatr Cogn Disord; 2005; 19(5-6):256-65. PubMed ID: 15785028
[TBL] [Abstract][Full Text] [Related]
5. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease.
Vega GL; Weiner MF; Lipton AM; Von Bergmann K; Lutjohann D; Moore C; Svetlik D
Arch Neurol; 2003 Apr; 60(4):510-5. PubMed ID: 12707064
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression.
Jahn T; Clark C; Kerksiek A; Lewczuk P; Lütjohann D; Popp J
J Steroid Biochem Mol Biol; 2021 Jan; 205():105785. PubMed ID: 33171206
[TBL] [Abstract][Full Text] [Related]
7. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid.
Riekse RG; Li G; Petrie EC; Leverenz JB; Vavrek D; Vuletic S; Albers JJ; Montine TJ; Lee VM; Lee M; Seubert P; Galasko D; Schellenberg GD; Hazzard WR; Peskind ER
J Alzheimers Dis; 2006 Dec; 10(4):399-406. PubMed ID: 17183151
[TBL] [Abstract][Full Text] [Related]
8. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease.
Carlsson CM; Gleason CE; Hess TM; Moreland KA; Blazel HM; Koscik RL; Schreiber NT; Johnson SC; Atwood CS; Puglielli L; Hermann BP; McBride PE; Stein JH; Sager MA; Asthana S
J Alzheimers Dis; 2008 Mar; 13(2):187-97. PubMed ID: 18376061
[TBL] [Abstract][Full Text] [Related]
9. High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels.
Thelen KM; Laaksonen R; Päivä H; Lehtimäki T; Lütjohann D
J Clin Pharmacol; 2006 Jul; 46(7):812-6. PubMed ID: 16809807
[TBL] [Abstract][Full Text] [Related]
10. Plasma 24S hydroxycholesterol response to statins in Alzheimer's disease patients: effects of gender, CYP46, and ApoE polymorphisms.
Vega GL; Weiner MF
J Mol Neurosci; 2007 Sep; 33(1):51-5. PubMed ID: 17901546
[TBL] [Abstract][Full Text] [Related]
11. Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein.
Sjögren M; Gustafsson K; Syversen S; Olsson A; Edman A; Davidsson P; Wallin A; Blennow K
Dement Geriatr Cogn Disord; 2003; 16(1):25-30. PubMed ID: 12714796
[TBL] [Abstract][Full Text] [Related]
12. Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults.
Li G; Mayer CL; Morelli D; Millard SP; Raskind WH; Petrie EC; Cherrier M; Fagan AM; Raskind MA; Peskind ER
Neurology; 2017 Sep; 89(12):1251-1255. PubMed ID: 28821686
[TBL] [Abstract][Full Text] [Related]
13. Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins.
Höglund K; Wiklund O; Vanderstichele H; Eikenberg O; Vanmechelen E; Blennow K
Arch Neurol; 2004 Mar; 61(3):333-7. PubMed ID: 15023808
[TBL] [Abstract][Full Text] [Related]
14. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial.
Simons M; Schwärzler F; Lütjohann D; von Bergmann K; Beyreuther K; Dichgans J; Wormstall H; Hartmann T; Schulz JB
Ann Neurol; 2002 Sep; 52(3):346-50. PubMed ID: 12205648
[TBL] [Abstract][Full Text] [Related]
15. Alterations in cholesterol metabolism as a risk factor for developing Alzheimer's disease: Potential novel targets for treatment.
Loera-Valencia R; Goikolea J; Parrado-Fernandez C; Merino-Serrais P; Maioli S
J Steroid Biochem Mol Biol; 2019 Jun; 190():104-114. PubMed ID: 30878503
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia.
Recto CS; Acosta S; Dobs A
Clin Cardiol; 2000 Sep; 23(9):682-8. PubMed ID: 11016019
[TBL] [Abstract][Full Text] [Related]
17. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
[TBL] [Abstract][Full Text] [Related]
18. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia.
Assmann G; Kannenberg F; Ramey DR; Musliner TA; Gutkin SW; Veltri EP
Curr Med Res Opin; 2008 Jan; 24(1):249-59. PubMed ID: 18053317
[TBL] [Abstract][Full Text] [Related]
19. Potential diagnostic applications of side chain oxysterols analysis in plasma and cerebrospinal fluid.
Leoni V; Caccia C
Biochem Pharmacol; 2013 Jul; 86(1):26-36. PubMed ID: 23541982
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease.
Solomon A; Leoni V; Kivipelto M; Besga A; Oksengård AR; Julin P; Svensson L; Wahlund LO; Andreasen N; Winblad B; Soininen H; Björkhem I
Neurosci Lett; 2009 Oct; 462(1):89-93. PubMed ID: 19560513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
